Laboratorios Farmaceuticos Rovi (ROVI) Investor Update summary

Strategic rationale and transaction overview

• Acquisition of a state-of-the-art injectable drug product manufacturing site in Phoenix, Arizona, with over $100 million CapEx investments since 2021 and a total size of ~34,000 m².

• The facility offers advanced cytotoxic manufacturing capabilities, FDA, EMA, and Japanese agency approvals, and ample space for future expansion in biologics and high-value injectables.

• A new Optima prefilled syringe filling line with isolator technology will be installed by 2027, adding 65–70 million units of annual capacity.

• Five-year toll manufacturing agreement with Bristol Myers Squibb ensures a minimum annual payment of $50 million, totaling $250 million for the initial term.

• The acquisition price is not material for the acquirer and is below 1% of market cap; closing is expected in H1 2026, subject to regulatory approvals.

Growth opportunities and integration plans

• The Phoenix site strengthens the global manufacturing network, enabling end-to-end CDMO services across the U.S. and Europe.

• Expansion plans include new biologics manufacturing areas and leveraging the site for high-value products like vaccines, biosimilars, monoclonal antibodies, and ADCs.

• Integration strategy focuses on seamless transition, workforce retention, leveraging local talent, and logistics advantages.

• The new PFS and packaging lines will be operational by 2027, with CapEx for the new line estimated at $20–30 million.

• Post-integration, the company will operate five CDMO sites, increasing aseptic filling and packaging line capacity.

Financial and operational impact

• The five-year BMS contract covers operational costs but is not expected to be accretive in the first years; profitability will increase as new customers are added.

• Peak revenues from the new Optima line could exceed $100 million annually, depending on market demand.

• The facility offers unique value with high-potency cytotoxic and lyophilization capabilities, previously lacking in the network.

• The transaction positions the company as a top-three global CDMO injectable player, with five sites and over 1,400 employees.

• Long-term margins at the Phoenix site are expected to be comparable to those in Spain once fully ramped.